Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal
muscle mass, along with adipose tissue wasting, systemic inflammation and other metabolic …

Cells use mitophagy to remove dysfunctional or excess mitochondria, frequently in response
to imposed stresses, such as hypoxia and nutrient deprivation. Mitochondrial cargo …

Cachexia remains an underdiagnosed and undertreated, complex condition which includes
'objective'components (eg inadequate food intake, weight loss, inactivity, loss of muscle …

Most patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced
disease and survive less than 12 months. PDAC has been linked with obesity and glucose …

Interleukin (IL)‐6 is a cytokine with pleiotropic functions in different tissues and organs.
Skeletal muscle produces and releases significant levels of IL‐6 after prolonged exercise …

Patients with cancer are at particularly high risk for malnutrition because both the disease
and its treatments threaten their nutritional status. Yet cancer-related nutritional risk is …

Metabolic dysfunction contributes to the clinical deterioration observed in advanced cancer
patients and is characterized by weight loss, skeletal muscle wasting, and atrophy of the …

The genome of pancreatic ductal adenocarcinoma (PDAC) frequently contains deletions of
tumour suppressor gene loci, most notably SMAD4, which is homozygously deleted in …

Up to 85% of patients with pancreatic cancer have diabetes or hyperglycaemia, which
frequently manifests as early as 2–3 years before a diagnosis of pancreatic cancer …

Cancer cachexia is a complex disorder that is driven by inflammation and metabolic
imbalances, resulting in extreme weight loss. Adipose tissue, a main player in cancer …